Journal article

Simultaneous Binding of the Anti-Cancer IgM Monoclonal Antibody PAT-SM6 to Low Density Lipoproteins and GRP78

Zachary Rosenes, Yee-Foong Mok, Shuo Yang, Michael DW Griffin, Terrence D Mulhern, Danny M Hatters, Frank Hensel, Geoffrey J Howlett



Awarded by ARC

Funding Acknowledgements

This work is supported by an ARC linkage grant (LP100100392) and by Patrys Ltd, a company currently conducting clinical trials of PAT-SM6 as a potential anti-cancer treatment. FH is the managing director of Patrys, GmbH. The PAT-SM6 antibody is proprietary to Patrys Limited and the company agrees to make to make freely available any materials and information described in their publication that may be reasonably requested for the purpose of academic, non-commercial research. Due to the proprietary nature of the antibody parties will need to enter into a material transfer agreement. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.